Articles tagged with Attention Deficit Hyperactivity Disorder
A new training program has been shown to improve the diagnosis and treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in school-aged children. The program, developed by Cincinnati Children's Hospital Medical Center, focused on implementing standardized evidence-based guidelines for ADHD diagnosis and treatment.
A study found that Ritalin works in the prefrontal cortex to enhance cognition and focus, while having limited effects elsewhere. The medication tunes neuron sensitivity to signals, leading to improved cognitive function and attention.
A study by researchers from UWM found that a specific version of the DRD4 gene appears to have different effects depending on one's environment. In nomadic Ariaal men with the 7R allele variant, this gene is linked to better health and nourishment.
A long-term safety study on Lialda found that the medication is generally well-tolerated, with most adverse events being mild or moderate in intensity. The study also showed that a majority of patients remained in remission for 12 months.
A study published in JAMA found that St. John's wort did not improve ADHD symptoms in children and adolescents. The trial involved 54 participants who received either St. John's wort or a placebo for eight weeks, with no significant differences in symptom improvement.
A study found that students who slept less than eight hours per night had lower GPAs and were more likely to experience emotional disturbances. The research suggests that getting enough sleep is crucial for adolescents' psychological functioning and can have serious consequences.
A study of Kenyan nomads found that an ADHD-associated gene variant is linked to better health in the nomadic population, but malnourishment in settled individuals. This suggests that behavior differences associated with ADHD may be more or less effective depending on the environment.
Research published in Occupational and Environmental Medicine reveals that individuals with ADHD complete 1 month's worth of work in a year. Employers may benefit from implementing workplace screening programs to support affected workers, as effective treatments can improve performance.
A phase III pivotal study showed VYVANSE significantly improved ADHD symptoms in adults, including inattention and hyperactivity. The medication provided a 43% reduction in ADHD Rating Scale (ADHD-RS-IV) scores and was associated with a 60% improvement rate on the Clinical Global Impressions-Improvement (CGI-I) scale.
INTUNIV, a selective alpha-2A receptor agonist, demonstrated significant efficacy in reducing ADHD symptoms across all measured time points up to 24 hours postdose. The medication showed improved symptoms of ADHD in patients treated with INTUNIV compared to those receiving placebo.
A new data analysis confirms DAYTRANA's effectiveness in controlling ADHD symptoms in both boys and girls for up to 12 months. The study found that children with ADHD experienced significant improvements in symptom control, with lower scores on the ADHD Rating Scale.
Shire will present efficacy and safety results for its ADHD treatments, including lisdexamfetamine dimesylate, methylphenidate transdermal system, and guanfacine extended release. The presentations aim to contribute to the growing body of research on ADHD treatment options.
Sleep problems are extremely common in children with ADHD, associated with poorer child psychosocial quality of life and caregiver mental health. The prevalence of mild to moderate sleep problems was found to be significant, with difficulties falling asleep and resisting bedtime being common symptoms.
A study examines childhood ADHD in underrepresented minorities, highlighting obstacles faced by families and providing recommendations for assessment and treatment. Effective treatments exist, but many minority children lack culturally sensitive assessments, potentially leading to devastating results.
Adolescent girls with ADHD are more likely to develop body-image dissatisfaction and binge-eating behaviors, according to a new study. The study found that these girls may be at risk for eating disorders, depression, and anxiety due to impulsive behaviors.
A new study found that methylphenidate treatment improved sleep parameters in adults with ADHD, including increased sleep efficiency and a feeling of improved restorative value. The study also showed that objective and subjective sleep problems in adults with ADHD are identical to those in children with ADHD.
A new study found that stimulant treatment for children with ADHD has no effect on their future risk of substance abuse. The 10-year follow-up study analyzed over 100 young men and controlled for conditions like conduct disorder, which are associated with substance abuse.
A new UCLA study found that only half of children diagnosed with ADHD exhibit cognitive defects, challenging the common method for diagnosing the disorder. The research also suggested that medication is not always effective in treating ADHD, highlighting the need for alternative approaches to address long-term problems.
A new study predicts a 10-fold increase in ADHD prescription costs for the NHS, rising from £7m to £49-101m by 2012. The research modelled various scenarios and considered factors such as drug availability, diagnosis rates, and treatment levels.
Researchers at John Carroll University have developed blue-blocking glasses that block blue light to reduce ADHD symptoms and improve sleep patterns. The glasses work by advancing the circadian rhythm, leading to a marked decline in ADHD symptoms and promoting better sleep.
Youth with ADHD exhibit delayed brain maturation in frontal cortex areas, which can affect higher-order executive control functions. However, the delay is most pronounced in regions at the front of the brain's outer mantle, supporting ability to control thinking, attention, and planning.
A national survey of parents with children aged 6-17 found that 60% reported their child's medication stopped working before 6 p.m. This suggests a need for reassessment of treatment duration and potential factors contributing to the perceived ineffectiveness.
A study of psychiatrists and parents found significant differences in perceptions of pediatric ADHD and psychiatric comorbidities. The researchers suggest that improving communication between psychiatrists, parents, and patients can lead to better treatment outcomes for children with complicated ADHD.
The NIEHS has awarded grants totaling $3.5 million to seven outstanding young environmental scientists. These researchers will investigate the mechanisms of environmental exposures and human biology, human pathophysiology, and human disease.
Researchers found that insulin levels affect dopamine systems in the brain, which are involved in drug addiction and neuropsychiatric conditions. In diabetic animals, amphetamine-induced dopamine signaling was disrupted, suggesting a link between insulin status and brain function.
Research suggests that computerized working memory training can improve executive functioning and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children. This innovative approach offers a promising therapeutic strategy for alleviating the condition's impact on daily functioning.
A Mayo Clinic study of nearly 5,000 children with ADHD found that treatment with prescription stimulants was associated with improved long-term academic success. The study also showed that girls with untreated ADHD were equally vulnerable to poor school outcomes as boys and may be at risk for being undertreated.
A new study reveals that Pycnogenol, an antioxidant plant extract, lowers ADHD symptoms in children by reducing stress hormones. The findings suggest a significant stress hormone-lowering effect for a nutritional supplement, providing hope for parents seeking alternative treatments.
Research estimates that approximately 8.7 percent of U.S. children between the ages of 8 and 15 have attention-deficit/hyperactivity disorder (ADHD). Despite this prevalence, only a minority of affected children receive consistent treatment with ADHD medications.
A five-year study led by Lehigh University's College of Education identified effective nonmedicinal strategies to decrease aggressiveness and improve behavior in preschoolers with ADHD. The 'Project Achieve' study showed a 17-percent decrease in aggression and a 21-percent improvement in social skills for parents, while teachers saw a ...
A study found a gene variant associated with thinner brain tissue in areas handling attention, but also better clinical outcomes among individuals with ADHD. The 7-repeat form of the dopamine D4 receptor gene was linked to improved symptoms and regained brain thickness in affected individuals.
A specific gene variant associated with attention deficit hyperactivity disorder (ADHD) may also predict better clinical outcomes and higher IQ in teens. The variant, called the 7-repeat version of the dopamine D4 receptor gene, is linked to thinner brain areas controlling attention but confers advantage only among youth with ADHD.
Adults with ADHD show blunted response to methylphenidate, suggesting dopamine dysfunction may contribute to ADHD symptoms. Reduced dopamine activity is also associated with increased substance abuse in individuals with ADHD.
A new study published in SLEEP journal shows that methylphenidate (MPH) significantly improves vigilance performance in children with ADHD who have poor sleep efficiency. The researchers tested 37 children aged 6-12 and found a moderate increase in arousal levels, facilitating improved performance.
A study published in the Journal of Attention Disorders found that treatment rates for ADHD have increased rapidly across all age groups, with females showing the greatest increase. Improved diagnosis and changes in medication types contributed to this growth.
A new study by Dr. Lisa Strohschein found a significantly higher risk of Ritalin use among children whose parents divorce compared to those whose parents stay together. The research suggests that parental divorce may act as a stressful life event, leading to adjustment problems and increased ADHD symptoms.
A follow-up study found that pediatricians' behavioral health treatment methods showed only partial success, despite receiving structured interventions, FDA warnings, and mental health reforms. The interventions, including newsletters and resource guides, aimed to increase education on anxiety and depression recognition, collaboration ...
A recent study found that guanfacine extended release significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years. The investigational nonstimulant medication demonstrated clinically meaningful efficacy for up to 24 months of treatment.
A double-blind study found DAYTRANA significantly reduced ADHD symptoms in boys and girls aged 6-12 by 56.5% and 57.4%, respectively. The patch offers a favorable safety profile and provides a platform to discuss gender differences in ADHD treatment.
Long-term treatment with VYVANSE shows significant efficacy in ADHD, with 95% of children experiencing overall improvement after 12 months. The study also found consistent time to maximum concentration of d-amphetamine from patient to patient.
Daytrana demonstrated significant improvements in symptom control, tolerability, and safety in children with ADHD over a 12-month period. The study showed effective treatment of ADHD symptoms, with 83% and 78% of parents reporting 'very much improved' or 'much improved' outcomes.
Long-term study results show that LIALDA (mesalamine) is effective in maintaining remission and preventing relapse in patients with mild to moderate ulcerative colitis. Nearly 9 out of 10 patients on once-daily LIALDA remained relapse free at the end of 12 months.
A study found children with both autism and ADHD are four times more likely to bully than their peers, highlighting the need for additional support services.
A study investigates the impact of methylphenidate on young ADHD drivers' ability to focus while navigating real-world distractions. The research team aims to determine if controlled-release stimulant medication improves driving performance in such situations.
Researchers at Yale University have discovered a molecular mechanism that dynamically alters brain network connections, influencing working memory and cognitive function. Closing ion channels can strengthen connectivity, improving working memory and reducing distractibility.
Researchers discovered a molecular mechanism that strengthens brain networks by closing ion channels, which may improve working memory and reduce distractibility in conditions like ADHD. This discovery has implications for developing drug therapies for normal aging and treating cognitive changes in schizophrenia and bipolar disorder.
Research suggests that children with attention deficit hyperactivity disorder (ADHD) are more likely to develop alcohol problems, particularly those who experience heavy drinking and stress in childhood. Parental alcoholism and family dynamics also play a significant role in the development of alcohol use disorders among young adults.
A study published in the Journal of Clinical Sleep Medicine finds that adolescents with sleep disturbances are more likely to receive bad grades, experiencing symptoms such as restless legs, difficulty concentrating, and snoring. Parents and teens can improve school performance by following recommended sleep habits.
The FDA has approved LIALDA (mesalamine), the first oral once-daily mesalamine for patients with active, mild to moderate ulcerative colitis. Clinical trials found LIALDA effective in inducing remission compared to placebo after eight weeks of treatment.
A recent study by Vanderbilt University Medical Center researchers found that prenatal cocaine exposure in rabbits causes a long-lasting displacement of dopamine receptors in certain brain cells. This effect alters their ability to function normally and may lead to subtle cognitive impairments, attention deficits, and emotional problems.
Researchers found lower levels of dopamine transporters in certain brain regions of ADHD patients compared to controls. ADHD patients experienced higher levels of inattention despite similar dopamine transporter levels, indicating a complex relationship between dopamine and attention.
A phase I clinical trial found that Shire's investigational drug SPD465 was bioequivalent to a combination of ADDERALL XR and mixed amphetamine salts immediate release. This suggests that SPD465 could offer full-day symptom control for adults with ADHD, potentially eliminating the need for augmenting long-acting stimulant medications.
A 25-year meta-analysis of 29 double-blind studies involving nearly 4,500 children with ADHD found that stimulant medications produced larger effect sizes than non-stimulants. The study suggests that amphetamine- and methylphenidate-based stimulants are more effective treatments for ADHD symptoms.
New data shows significant improvement in core symptoms of ADHD with guanfacine extended release, including hyperactivity, impulsivity, and inattention. The medication was well-tolerated with mild or moderate side effects.
The investigational amphetamine compound SPD465 demonstrated improved Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in adults for up to 16 hours post-dose. The study results showed that SPD465 provided significant improvement in ADHD symptom control based on PERMP and ADHD-RS scores.
A study found that adults with depressive disorder, Bipolar Disorder, or anxiety disorder are at risk of having undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), with 32.0% comorbid in those with depression and 21.2% in those with bipolar disorder. Researchers analyzed medical claims data to identify this comorbidity.
The DAYTRANA patch offers flexible wear times, allowing physicians to manage ADHD symptoms and minimize late-day side effects. The patch demonstrated significant efficacy in reducing ADHD symptoms, even when worn for shorter periods.
A phase 3 study demonstrated lisdexamfetamine dimesylate's effectiveness in reducing ADHD symptoms, with 95% of children showing significant improvement. The medication was well-tolerated, with side effects similar to those of marketed ADHD stimulants.
A new study finds methylphenidate, a widely prescribed ADHD drug, to be safe and effective in preschoolers when used at low doses. However, younger children may experience slower growth rates and side effects such as irritability and weight loss.
A long-term study found that preschoolers with ADHD benefit from low doses of methylphenidate, but may need higher doses later on to maintain effectiveness. The study also showed significant side effects, including growth rate changes and weight loss.